Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Shams

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Journal of Glaucoma|April 4, 2021
A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)Kenneth W Olander, Michelle A Sato, Marc A Abrams, et al.
Journal of Occupational Medicine. : Official Publication of the Industrial Medical Association|September 11, 1992
Cholylglycine measured in serum by RIA and interleukin-1 beta determined by ELISA in differentiating viral hepatitis from chemical liver injuryG Y Li, T Wang, E M Huggins, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|July 11, 2018
Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive MonkeysMasahiro Fuwa, Carol B Toris, Shan Fan, et al.
European Journal of Endocrinology|February 3, 2022
Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trialR A Ajjan, E M A Hensor, F Del Galdo, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Journal of Glaucoma|April 4, 2021
A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)Kenneth W Olander, Michelle A Sato, Marc A Abrams, et al.
Journal of Occupational Medicine. : Official Publication of the Industrial Medical Association|September 11, 1992
Cholylglycine measured in serum by RIA and interleukin-1 beta determined by ELISA in differentiating viral hepatitis from chemical liver injuryG Y Li, T Wang, E M Huggins, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|July 11, 2018
Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive MonkeysMasahiro Fuwa, Carol B Toris, Shan Fan, et al.
European Journal of Endocrinology|February 3, 2022
Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trialR A Ajjan, E M A Hensor, F Del Galdo, et al.
Pageof 4